Evidence suggest that HER2 CN of 10 and 9.5 is the optimal cutoff for predicting OS longer than 12 months and for OS longer than 16 months in HER2-positive advanced GC patients treated with trastuzumab, respectively (Gomez-Martin et al. 2013). Here, ERBB2 is linked to gastric cancer.